StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Organon by Year

Organon — Singulair (montelukast) Worldwide sales ($M) ($M)

QuarterlyAnnual

Merck Organon: $252,000,000M in FY2025, down 29.8% from a year earlier.

Latest, FY2025
252,000,000
Period ended Dec 31, 2025
Change on a year earlier
-29.8%
359,000,000 in FY2024
History
7 years
Since FY2019
Sources
4
Documents cited below

Where the FY2025 figure comes from

Source: Organon & Co. SEC Filing (0001628280-26-011125) ↗

Reported in Organon & Co. Form 10-Q / 10-K (CIK 0001821825).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOrganon — Singulair (montelukast) Worldwide sales ($M) ($M)Year on yearSource
FY2025Dec 31, 2025252,000,000-29.8%Organon & Co. SEC Filing (0001628280-26-011125) ↗
FY2024Dec 31, 2024359,000,000-11.1%Organon & Co. SEC Filing (0001821825-25-000006) ↗
FY2023Dec 31, 2023404,000,000-1.7%Organon & Co. SEC Filing (0001821825-25-000006) ↗
FY2022Dec 31, 2022411,000,000-0.5%Organon & Co. SEC Filing (0001821825-25-000006) ↗
FY2021Dec 31, 2021413,000,000-10.6%Organon & Co. SEC Filing (0001821825-23-000003) ↗
FY2020Dec 31, 2020462,000,000-33.8%Organon & Co. SEC Filing (0001821825-23-000003) ↗
FY2019Dec 31, 2019698,000,000–Organon & Co. SEC Filing (0001821825-22-000002) ↗

Breakdown

What makes up organon

Cite this data

StockData. (2026). Merck Organon ($M), annual FY2019–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/ogn-singulair-ww

See every metric in the Merck KPI table. Data updated Oct 26, 2026.